NMO Spectrum Disorder Clinical Trial
Official title:
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor that blocks the upregulated JAK-STAT pathway in patients with neuroimmune disorders, which is important in bone marrow regulation of B cell proliferation and differentiation. Baricitinib may benefit some patients with NMOSD due to the important role of B cells in the pathogenesis of NMOSD. Clincial trials may be needed to observe its efficacy and safety.
The investigators primarily aim to observe the time to first relapse from initiation of baricitinib treatment. The secondary outcomes are to determine: The safety profile of baricitinib in participants with NMO and whether baricitinib improves Expanded Disability Status Scale (EDSS), et al. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05154734 -
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03829566 -
Autologous Transplant To End NMO Spectrum Disorder
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
| Completed |
NCT05432713 -
A Study of LP-168 in Healthy Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT04822623 -
Imaging Evaluation of Central Nervous Autoimmune Diseases
|
||
| Completed |
NCT04227470 -
A Study of HBM9161 in NMOSD Patients
|
Phase 1 | |
| Not yet recruiting |
NCT06280755 -
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
|
||
| Recruiting |
NCT05414890 -
Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
|
||
| Recruiting |
NCT05840055 -
ACT With NMOSD Patients and Caregivers Pilot Study
|
N/A | |
| Recruiting |
NCT05004493 -
Biorepository and Registry for Plasma Exchange Patients
|
||
| Completed |
NCT05896605 -
Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder
|
Phase 4 | |
| Recruiting |
NCT04106830 -
Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE)
|
||
| Completed |
NCT03766347 -
Pediatric NMOSD Observational Study
|
||
| Recruiting |
NCT05154370 -
China National Registry of Neuro-Inflammatory Diseases
|
||
| Recruiting |
NCT05145361 -
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
|
Early Phase 1 | |
| Not yet recruiting |
NCT05974293 -
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
|
Phase 2 | |
| Completed |
NCT04355611 -
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
|